You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Preclinical Development of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)
SBC: Accuronix Therapeutics Inc Topic: 102Project Summary/Abstract Pancreatic cancer is a devastating disease with a very low (8%) 5-year survival rate. Therapeutic options are limited in efficacy and many have substantial toxicity. Targeted drug delivery may improve the therapeutic index of cancer drugs by enhancing drug localization to the cancer cell while minimizing off-target side effects. Sigma-2 receptors (S2R) are highly expressed ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A
SBC: Mitochondria in Motion, Inc. Topic: NINDSMitofusin agonists to prevent Charcot-Marie-Tooth disease 2A Gerald W Dorn II, MD Mitochondria in Motion, Inc. Washington University in St Louis School of Medicine Abstract: Charcot-Marie-Tooth (CMT) disease type 2A is an incurable, primarily pediatric, autosomal dominant neuromuscular degenerative disease caused by mutations in the mitofusin (MFN) 2 gene. There are currently no disease-altering t ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Mitofusin Agonists to Treat Neurodegenerative Disease
SBC: Mitochondria in Motion, Inc. Topic: 104Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn II, MD Mitochondria in Motion, Inc. Washington University in St Louis School of Medicine Abstract: A number of rare neurodegenerative diseases are characterized by mitochondrial fragmentation, dysmotility and dysfunction. Among these are Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD), which cause ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Isovolumetric Multimodal Venous Thrombectomy System
SBC: Caeli Vascular LLC Topic: NHLBIABSTRACTThis Phase II STTR application from Caeli Vascular, LLC entails a 24-month period focused on further development of a novel multi-modal venous thrombectomy device. The PI is a vascular surgeon with biomedical research and entrepreneurship experience, and is supported by a team of highly qualified investigators, including a vascular biologist, neurosurgeon, veterinarian, biomedical engineer ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Novel tetrahedron beam CT for point-of-care imaging in ear, nose and throat imaging
SBC: TETRAIMAGING LLC Topic: NIBIBABSTRACT Point-of-care imaging is highly desired in otolaryngologic clinics for the diagnosis of ear, nose and throat (ENT) diseases including cancers. Due to limited image quality, current cone-beam CT (CBCT) products act not as a substitute but rather as a complement to diagnostic Multi-slice CT (MSCT) in maxillofacial and ENT imaging. The emerging multi-source x-ray source technology suggests n ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute
SBC: KaloCyte Inc Topic: NHLBIPROJECT SUMMARY There is need for an artificial oxygenOcarrier to substitute for banked blood in settings wherestored blood is unavailablepre hospital care transportaustere environmentsundeveloped countriesorundesirabletransfusion risk exceeds benefitTo address this needwe developedErythroMerEMa first inclass nano cyte blood substituteEM is a deformablecross linked polymeric nanoparticle that inco ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
A Deep Learning Model to Improve Pathologist Interpretation of Donor Kidney Biopsies
SBC: NEWVENTUREIQ LLC Topic: 400ABSTRACT More people die every year from kidney disease than breast or prostate cancer. Kidney transplantation is life-saving, yet the donor organ shortage and high organ discard rate contributes to 13 deaths daily among patients awaiting transplant. The decision to use or discard a donor kidney relies heavily on microscopic quantitation of chronic damage by pathologists. The current standard of c ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of a Sunflower Crop for Large Scale Production of Natural Rubber
SBC: EDISON AGROSCIENCES INC Topic: ST18C001Natural rubber is an essential manufacturing material that possesses performance properties that are superior to synthetic rubber for many product applications, including increased tear and tensile strength, as well as superior mechanical performance properties. Aircraft tires, for example, are made of natural rubber; whereas, synthetic rubber (which is less expensive to procure) is used for less ...
STTR Phase II 2021 Department of DefenseDefense Advanced Research Projects Agency -
Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events
SBC: CAPELLA IMAGING, LLC Topic: NHLBIDespite the myriad major advances in cardiologythe prognosis for patients with severemedically refractive heart failureHFis exceedingly poorApproximatelydeaths occur annually in patients with HF who have endured an impaired quality of life often accompanied by significant economic and personal losses due to recurrent hospitalizationsAt leastof these deaths were directly related to severe heart fai ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel insulin-sensitizing NASH/diabetes drugs.
SBC: BIOIO, LLC Topic: 300Obesity is associated with an increased risk of a number of chronic and progressive diseases and obesity- related metabolic diseases constitute a significant public health burden. The increased likelihood of developing insulin resistance and diabetes is probably the most commonly recognized risk of being obese. In addition, obesity is also associated with accumulation of lipid in the liver parench ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health